Insider and congress filings

AbbVie Inc. (ABBV)

NYSE · Healthcare · 369 insider transactions · 202 congress trades · last filed 24 days agoS&P 500

4
Open-market insider filings shown
2d
Median delay on the insider filings, in business days
within the two business day rule
0 buys·4 sells
Purchases and sales in the filings shown
Get a push when an insider at AbbVie Inc. trades.

Free on iOS and Android.

About AbbVie Inc.

from the company's filings and listing, as of Oct 24, 2026
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Robert A. Michael
Employees
57,000
Listed since
Jan 2, 2013
Market value
$504.8B
Price to earnings (12 mo)
80.5
Net income per share, as reported (12 mo)
$3.57
Dividend yield
2.42%

www.abbvie.com

Company news

5 of 9 articles · newest first
HeadlineSourceDate
U.S. FDA approves subcutaneous induction for AbbVie's SKYRIZI in Crohn's diseaseThe induction doses are given by on-body injector at weeks 0, 2, 4 and 8, followed by maintenance doses every eight weeks starting at week 12.Company releaseOct 23, 2026
AbbVie to present new and updated data at 2026 ESMO Congress in MadridThe presentations cover seven assets across lung, colorectal, ovarian, prostate and gastric cancers.Company releaseOct 18, 2026
AbbVie presents 20 IBD abstracts with long-term Skyrizi and Rinvoq data at UEGW 2026The company said the meeting runs October 17 to 20 in Barcelona, Spain, and includes new endoscopic remission data for investigational ABBV-466 in Crohn's disease.Company releaseOct 17, 2026
AbbVie to present 22 inflammatory bowel disease abstracts at ACG 2026 meetingAbbVie said new Phase 3 AFFIRM data showed higher clinical and endoscopic response rates for subcutaneous SKYRIZI than placebo in Crohn's disease patients.Company releaseOct 11, 2026
AbbVie's Temab-A receives two FDA Breakthrough Therapy DesignationsThe designations cover colorectal cancer and non-small cell lung cancer, and are the first for the drug.Company releaseOct 7, 2026

Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. All 9 ABBV articles

Earnings

6 reported quarters · next on Oct 30, 2026
QuarterEPSEPS expectedRevenueRevenue expectedResult
Q2 FY2026reported Jul 31, 2026$3.65$3.61$17.0B$16.8BEPS in lineRevenue in line
Q1 FY2026reported Apr 29, 2026$2.65$2.59$15.0B$14.7BEPS beatRevenue beat
Q4 FY2025reported Feb 4, 2026$2.71$2.65$16.6B$16.4BEPS beatRevenue in line
Q3 FY2025reported Oct 31, 2025$1.86$1.77$15.8B$15.6BEPS beatRevenue in line
Q2 FY2025reported Jul 31, 2025$2.97$2.88$15.4B$15.0BEPS beatRevenue beat
Q1 FY2025reported Apr 25, 2025$2.46$2.38$13.3B$12.9BEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Executive pay

as filed for fiscal 2025 · proxy filed Mar 23, 2026
ExecutiveSalaryStock awardsOtherTotal
Robert A. MichaelChairman of the Board and Chief Executive Officer$1.7M$13.3M$17.6M$32.5M
Jeffrey R. StewartExecutive Vice President, Chief Commercial Officer$1.3M$5.4M$8.7M$15.4M
Scott T. ReentsExecutive Vice President, Chief Financial Officer$1.1M$4.4M$6.9M$12.4M
Azita Saleki-GerhardtExecutive Vice President, Chief Operations Officer$1.1M$4.0M$5.8M$10.8M
Roopal B. ThakkarExecutive Vice President, Research & Development and Chief Scientific Officer$1.1M$4.0M$4.8M$9.9M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

Institutional holders

13F positions as of Jun 30, 2026
HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$37.6B149,488,412-0.8%8.44%
Vanguard Capital Management LLC$29.0B115,396,098+0.4%6.52%
State Street Corp$20.8B82,596,748+1.7%4.66%
Vanguard Portfolio Management LLC$12.2B48,477,996-2.1%2.74%
JPMorgan Chase & Co.$12.2B47,862,796-15.6%2.70%
Geode Capital Management, LLC$11.8B46,998,433+0.6%2.65%
Morgan Stanley$9.8B38,901,001+2.3%2.20%
Capital Research Global Investors$7.6B30,101,551-3.7%1.70%
Norges Bank$6.4B25,554,538New1.44%
Bank of America Corp$5.3B21,237,764-11.3%1.20%
FMR LLC$5.2B20,773,786-4.5%1.17%
Northern Trust Corp$5.2B20,558,447-3.1%1.16%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

Tracked fund managers holding ABBV

3 managers
ManagerValueSharesShare of book
Adage Capital Partners$402.3M1,598,5680.6%
Woodline Partners$228.3M907,3630.7%
Glenview CapitalLarry Robbins$37.5M148,9130.7%

3 of the 97 fund managers we track list ABBV shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Know when the next ABBV filing is reported.

GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.

Open-market insider trades

4 filings shown · newest filing first
InsiderActionSharesPriceValueTrade dateDelay
(business days)
Nicholas DonoghoeEVP, Chief BUS/Strat OfficerSold32,710$250.00$8.2MAug 14, 2026filed Aug 18, 20262d
David Ryan PurdueSVP, ControllerSold5,230$233.56$1.2MMar 4, 2026filed Mar 6, 20262d
Perry C. SiatisEVP, GC and SecretarySold · scheduled · 3 lines18,668$234.39$4.4MMar 2, 2026filed Mar 3, 20261d
Perry C. SiatisEVP, GC and SecretarySold · scheduled22,381$230.00$5.1MFeb 25, 2026filed Feb 27, 20262d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (20)
InsiderEventSharesDate
Edward J. RappDirectorStock award129Sep 30, 2026
Susan E. QuagginDirectorStock award59Sep 30, 2026
Nicholas DonoghoeEVP, Chief BUS/Strat OfficerOption exercise32,710Aug 14, 2026
Susan E. QuagginDirectorStock award62Jun 30, 2026
Edward J. RappDirectorStock award134Jun 30, 2026
Roxanne S. AustinDirectorStock award1,118May 8, 2026
William H.L. BurnsideDirectorStock award1,118May 8, 2026
Jennifer L. DavisDirectorStock award1,118May 8, 2026
Thomas C. FreymanDirectorStock award1,118May 8, 2026
Brett J. HartDirectorStock award1,118May 8, 2026
Melody B. MeyerDirectorStock award1,118May 8, 2026
Susan E. QuagginDirectorStock award1,118May 8, 2026
Edward J. RappDirectorStock award1,118May 8, 2026
Rebecca B. RobertsDirectorStock award1,118May 8, 2026
Frederick H. WaddellDirectorStock award1,118May 8, 2026
Thomas J. FalkDirectorStock award1,118May 8, 2026
Robert J. AlpernDirectorStock award35Mar 31, 2026
Edward J. RappDirectorStock award155Mar 31, 2026
Susan E. QuagginDirectorStock award71Mar 31, 2026
David Ryan PurdueSVP, ControllerTax withholding2,108Feb 27, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

Congress trades in ABBV

20 disclosures of 202 on record · median 28d of the 45 allowed

Since the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.

MemberTypeActionAmount disclosedStock since the tradeTrade dateDisclosedDelay
Pete SessionsStockSale$15,001 - $50,000+9.1%After the saleS&P 500 -0.1% · +9.2 pts vs S&P 500Sep 14, 2026Sep 18, 20264d
Alan ArmstrongSelfStockPurchase$15,001 - $50,000+36.4%S&P 500 +19.8% · +16.6 pts vs S&P 500Mar 27, 2026Jul 21, 2026116d
Ro KhannaStockPurchase$1,001 - $15,000+32.6%S&P 500 +0.1% · +32.6 pts vs S&P 500Jun 2, 2026Jul 6, 202634d
Ro KhannaStockPurchase$15,001 - $50,000+38.3%S&P 500 +5.4% · +32.8 pts vs S&P 500May 1, 2026Jun 9, 202639d
Ro KhannaStockPurchase$15,001 - $50,000+35.8%S&P 500 +2.8% · +33.0 pts vs S&P 500May 15, 2026Jun 9, 202625d
Josh GottheimerJointStockSale$1,001 - $15,000+38.6%After the saleS&P 500 +5.0% · +33.6 pts vs S&P 500May 5, 2026Jun 3, 202629d
Ro KhannaStockSale$15,001 - $50,000+38.3%After the saleS&P 500 +10.8% · +27.6 pts vs S&P 500Apr 13, 2026May 11, 202628d
Ro KhannaStockSale$15,001 - $50,000+34.0%After the saleS&P 500 +20.3% · +13.8 pts vs S&P 500Mar 30, 2026Apr 7, 20268d
Ro KhannaStockPurchase$15,001 - $50,000+30.4%S&P 500 +12.1% · +18.3 pts vs S&P 500Feb 5, 2026Mar 9, 202632d
Ro KhannaStockPurchase$1,001 - $15,000+30.3%S&P 500 +10.2% · +20.1 pts vs S&P 500Jan 23, 2026Feb 6, 202614d
Ro KhannaStockSale$15,001 - $50,000+29.6%After the saleS&P 500 +9.5% · +20.1 pts vs S&P 500Jan 29, 2026Feb 6, 20268d
Julie JohnsonJointStockSale$1,001 - $15,000+28.2%After the saleS&P 500 +12.3% · +15.9 pts vs S&P 500Dec 18, 2025Jan 15, 202628d
Julia LetlowFiled lateStockPurchase$1,001 - $15,000+52.0%S&P 500 +31.5% · +20.5 pts vs S&P 500Oct 23, 2024Jan 13, 2026447d
Julia LetlowFiled lateStockSale$1,001 - $15,000+67.7%After the saleS&P 500 +25.0% · +42.8 pts vs S&P 500Jan 24, 2025Jan 13, 2026354d
Julia LetlowFiled lateStockPurchase$1,001 - $15,000+48.5%S&P 500 +37.9% · +10.6 pts vs S&P 500Apr 28, 2025Jan 13, 2026260d
Julia LetlowStockSale$1,001 - $15,000+28.0%After the saleS&P 500 +11.1% · +16.9 pts vs S&P 500Dec 8, 2025Jan 13, 202636d
Julie JohnsonJointStockSale$1,001 - $15,000+23.0%After the saleS&P 500 +13.0% · +9.9 pts vs S&P 500Nov 13, 2025Dec 11, 202528d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+25.2%S&P 500 +11.7% · +13.4 pts vs S&P 500Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+25.2%After the saleS&P 500 +11.7% · +13.4 pts vs S&P 500Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+31.0%After the saleS&P 500 +11.4% · +19.6 pts vs S&P 500Oct 31, 2025Nov 21, 202521d

Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in ABBV, filterable by party, chamber, type and account.

Members of Congress reporting a position

22 members · estimate, as of Oct 23, 2026

22 members report a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.

MemberParty, chamberEstimated positionShare of their portfolio
John W. HickenlooperDemocrat · Senate$500,001 - $1,000,0002.3%
J. French HillRepublican · House$250,001 - $500,0001.8%
Rick W. AllenRepublican · House$100,001 - $250,0003.4%
Gary C. PetersDemocrat · Senate$100,001 - $250,0003.1%
Carol D. MillerRepublican · House$50,001 - $100,0003.8%
Gilbert Ray Cisneros, Jr.Democrat · House$50,001 - $100,0000.3%
Kelly MorrisonDemocrat · House$50,001 - $100,0000.6%
Robert BresnahanRepublican · House$50,001 - $100,0000.6%
Randy FineRepublican · House$50,001 - $100,0004.2%
Jared MoskowitzDemocrat · House$50,001 - $100,0001.3%
Tommy TubervilleRepublican · Senate$50,001 - $100,0001.6%
Virginia FoxxRepublican · House$15,001 - $50,0002.6%
Michael A. RulliRepublican · House$1,001 - $15,0001.0%
Robert J. WittmanRepublican · House$1,001 - $15,0001.0%
Cliff BentzRepublican · House$1,001 - $15,0000.6%
Daniel MeuserRepublican · House$1,001 - $15,0000.4%
Dwight EvansDemocrat · House$1,001 - $15,0006.1%
John McGuireRepublican · House$1,001 - $15,0002.1%
Julie JohnsonDemocrat · House$1,001 - $15,0000.1%
Lucy McBathDemocrat · House$1,001 - $15,0000.2%
Robert B. AderholtRepublican · House$1,001 - $15,0001.2%
Pete SessionsRepublican · House$1,001 - $15,0000.1%

Estimate, as of Oct 23, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Questions

Are insiders buying or selling ABBV?

Across the 4 most recent open-market filings shown here, 0 were purchases and 4 were sales. 2 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded ABBV?

Pete Sessions, Alan Armstrong, Ro Khanna, Josh Gottheimer, Julie Johnson, Julia Letlow and others disclosed ABBV transactions in the filings shown here.

Which members of Congress hold ABBV?

22 members of Congress report a position in ABBV in the estimate we hold as of Oct 23, 2026. The two largest estimated positions belong to John W. Hickenlooper and J. French Hill; Rick W. Allen holds one of the next largest, in the $100,001 - $250,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

Is ABBV in the S&P 500 or the Nasdaq 100?

AbbVie Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.

How quickly are ABBV trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.

How to read a Form 4

A DECISION THE INSIDER MADE

POpen-market purchase. Bought with their own money at the market price.
SOpen-market sale. Sold on the market. A sale marked scheduled was set up in advance under a Rule 10b5-1 plan, often months before.

COMPENSATION PLUMBING

AStock award. Granted as pay, not bought.
MOption exercise. Converting options already held into shares.
FTax withholding. Shares handed back to the company to pay the tax on a grant.
GGift. Given away, with no money changing hands.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

Data as of Oct 26, 2026.

Related companies

traded by the same members

See every company we track